Board certified medical oncologist with primary expertise in the translational and clinical development of immunotherapies, inclusive of PD-L1 inhibitors, therapeutic cancer vaccines, immune suppressor modulator (anti-IL-8), IDO inhibitor, adoptive NK cells, IL-15RA, neo-epitope vaccine strategy, use of standard therapeutics to induce immunogenic modulation (radiation and chemotherapy), first ever immunotherapy to target a transcription factor called brachyury, and the first ever randomized phase 2 trial in rare disease (chordoma) using a therapeutic cancer vaccine.Leadership of multifunctional development organizations in industry and at the NCI, with responsibility for budgets, team structure, reporting lines, functional disciplines and administration. Trained at the National Cancer Institute with the Laboratory of Tumor Immunology and Biology. Mentored by Dr. Jeffrey Schlom, Dr. James Gulley, and Dr. Ravi Madan. Research interests: Cancer Immunotherapy; Cancer Vaccines; Identifying meaningful surrogates for patient outcomes in trials using cancer vaccinesTraining: Clinical focus in translational research; Trial management; Trial designSpecialties: Clinical Trials (strategy, design, writing, management, data analysis, regulatory interactions)Clinical Translational Science